[HTML][HTML] The effects of CypA on apoptosis: potential target for the treatment of diseases
L Chen, Z Zeng, H Luo, H Xiao, Y Zeng - Applied Microbiology and …, 2024 - Springer
Cyclophilin A (CypA), the first member of cyclophilins, is distributed extensively in eukaryotic
and prokaryotic cells, primarily localized in the cytoplasm. In addition to acting as an …
and prokaryotic cells, primarily localized in the cytoplasm. In addition to acting as an …
[HTML][HTML] Targeting Mcl-1 degradation by Bergenin inhibits tumorigenesis of colorectal cancer cells
Myeloid leukemia 1 (Mcl-1) is frequently overexpressed in human malignancies and
emerged as a promising drug target. In this study, we verified the inhibitory effect of bergenin …
emerged as a promising drug target. In this study, we verified the inhibitory effect of bergenin …
Anti‐apoptotic protein BCL‐XL as a therapeutic vulnerability in gastric cancer
Y Wei, L Zhang, C Wang, Z Li, M Luo… - Animal Models and …, 2023 - Wiley Online Library
Background New therapeutic targets are needed to improve the outcomes for gastric cancer
(GC) patients with advanced disease. Evasion of programmed cell death (apoptosis) is a …
(GC) patients with advanced disease. Evasion of programmed cell death (apoptosis) is a …
PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment
RB Kargbo - ACS Medicinal Chemistry Letters, 2023 - ACS Publications
The anti-apoptotic BCL-2 protein family members, including BCL-2, BCL-XL, and MCL-1,
have been established as promising therapeutic targets for cancer treatment, as evidenced …
have been established as promising therapeutic targets for cancer treatment, as evidenced …
Emerging proteolysis targeting antibodies (PROTABs) for application in cancer therapy
RB Kargbo - ACS Medicinal Chemistry Letters, 2022 - ACS Publications
The emerging proteolysis targeting antibodies (PROTABs) offer an attractive technology that
circumvents some of the challenges of small-molecule intracellular degraders with limited …
circumvents some of the challenges of small-molecule intracellular degraders with limited …
Design, synthesis, and evaluation of BCL‐2 targeting PROTACs
BCL‐2, a member of the BCL‐2 protein family, is an antiapoptotic factor that regulates the
intrinsic pathway of apoptosis. Due to its aberrant activity, it is frequently implicated in …
intrinsic pathway of apoptosis. Due to its aberrant activity, it is frequently implicated in …
Potent and Selective BCL-XL Inhibitors and PROTAC Compounds as Potential Cancer Treatment and Immunotherapy
RB Kargbo - ACS Medicinal Chemistry Letters, 2023 - ACS Publications
The B-cell lymphoma 2 (BCL-2) protein is the most extensively studied anti-apoptotic
member within the BCL-2 protein family. It functions to inhibit programmed cell death by …
member within the BCL-2 protein family. It functions to inhibit programmed cell death by …
The Effect of Resistance Training on Some Markers of Apoptosis Caused by Diabetic Cardiomyopathy and Morphine withdrawal Syndrome in Diabetic Male Rats
M Sadegh Joola, A Saremi… - Journal of Jiroft University …, 2023 - journal.jmu.ac.ir
Materials and Methods: In this experimental study, 32 male wistar rats were randomly
divided into 4 groups with 8 rats, including diabetes, morphine diabetes, diabetes+ …
divided into 4 groups with 8 rats, including diabetes, morphine diabetes, diabetes+ …
Deep Learning-Driven Discovery of FDA-Approved BCL2 Inhibitors: In Silico Analysis Using a Deep Generative Model NeuralPlexer for Drug Repurposing in Cancer …
Finding strong inhibitors of the BCL2 target, which is essential for controlling apoptosis and
ensuring the survival of cancer cells, has prompted research into FDA-approved drugs. This …
ensuring the survival of cancer cells, has prompted research into FDA-approved drugs. This …